n−3 Fatty acids ameliorate hepatic steatosis and dysfunction after LXR agonist ingestion in mice

► LXR agonist and saturated fat ingestion lead to hepatic steatosis and dysfunction. ► n−3 fatty acids decrease LXR agonist-mediated hepatic steatosis. ► This is linked to decreasing hepatic SREBP-1c and fatty acid synthase mRNA. ► n−3 diet also normalizes LXR agonist-mediated increases of hepatotoxicity.